Side Area Image
Novita Healthcare Limited (ASX:NHL) is an Australian Medical Technology Company listed on the Australian Securities Exchange. Novita's core focus is the development of TALI Health and the TALI Technology.
1300 082 013
info@novitahealthcare.com.au

Executive Committee

HomeAbout UsExecutive Committee

DR HANNAH KIRK

Chief Research Officer

Dr Kirk is a developmental neuroscientist who completed her PhD at Monash University in the Institute of Cognitive and Clinical Neurosciences.

MAGDA KLAPAKIS

Financial Controller

Ms Klapakis has been with Avexa since its inception and brings over 25 year’s of professional experience including significant engagement in the healthcare industry.

JOHN OSBORNE

Company Secretary

Over 30 years of senior financial, administrative, commercial and company secretarial experience with ASX listed companies.

Dr Kirk was one of the inventors of the TALI system and conducted the first clinical trial to evaluate the benefits of this Technology.

Dr Kirk has published 10 peer-reviewed articles in highly regarded journals, presented at both national and international conferences and been the recipient of several research and industry based awards.  She currently retains an Adjunct Research Fellowship in the Institute of Cognitive and Clinical Neurosciences at Monash University.

As part of the TALI Health team, Dr Kirk’s goal is to design scientifically driven tasks that benefit cognition and behaviour in both typically developing children and clinical populations.

She started her career with National Mutual Holdings (NMH) in a range of senior financial positions. During that time she was seconded for twelve months to the NSP Buck to set up their Finance Department, before returning to develop and maintain the NMH Forecast Model that was used in the successful demutualisation and subsequent listing of the company on the ASX as AXA Asia Pacific.

Magda moved into the Healthcare services sector in 2001 when she joined Endeavour Healthcare as their Finance Manager. She started working for listed biotech entity Amrad Corporation (later renamed Zenyth Therapeutics) in early 2003 before joining Avexa.

John Osborne has a wealth of practical and senior level financial, administrative and commercial experience across a broad range of industries spanning over 40 years.

Over the past twelve years he has focussed upon the provision of company secretarial services to eight ASX listed companies

John is Bachelor of Science (Monash), holds a Fellowship Diploma from RMIT (Management) and holds a Graduate Diploma of Applied Corporate Governance. He is an Associate member of the Governance Institute of Australia and a Chartered Secretary.